Pushing closer to a new cancer-fighting strategy

December 11, 2018

A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The finding, published Nov. 7 in Nature Communications, could eventually lead to new targets for cancer-fighting therapeutics.

This pathway, known as Ras-ERK, involves two important families of proteins. The first, known as Ras, is a group of enzymes that sends signals from the cell membrane to activate other proteins inside the cells. These Ras-activated proteins include a family of proteins known as extracellular signal-related kinases (ERK). Together, Ras and ERK ultimately play roles in cell proliferation, differentiation, metabolism and motility--physiological processes that often go awry in cancer.

Indeed, explains Chuan-Hsiang "Bear" Huang, M.D., Ph.D., assistant professor in the Department of Pathology at the Johns Hopkins University School of Medicine, the Ras-ERK pathway has been extensively investigated as a potential target for anti-cancer drugs since it's frequently mutated in various cancers. However, Huang says, these therapeutics have been met with challenging issues of efficacy and resistance largely because it remains unclear exactly how the different elements in this pathway work together.

For example, recent single-cell studies have shown that ERK activation happens in pulses. However, these pulses have appeared to occur without changes in Ras activity, even though it's been well established that Ras is needed to activate ERK.

To better understand this phenomenon, Jr-Ming Yang, a postdoctoral fellow, used several microscopy techniques to see when and where Ras and ERK activity occurred in cells. By tagging each protein with a differently colored fluorescent molecule that glowed when each protein activated, Yang confirmed that ERK activity occurred in pulses, as other studies had shown. However, rather than happening in response to Ras activation occurring cellwide, these ERK pulses were triggered when Ras activated discretely at patches along the cell membrane. A further look showed that Ras became activated at spots where the cell membrane protruded, as if the cell was probing its environment, says Yang.

To make sure that ERK pulses conjoined with Ras protrusions were a universal phenomenon, the researchers used the same techniques to look at different types of cells with a broad range of activity in this pathway. For example, they found that in ovarian cancer cells that displayed high Ras-ERK activity, the large number of ERK pulses was accompanied by an equally large number of Ras-associated protrusions; conversely, in breast and cervical cancer cells that had lower Ras-ERK activity, fewer ERK pulses were accompanied by lower numbers of protrusions, suggesting that these events were indeed linked.

Looking for the mechanism behind this effect, the researchers perturbed various proteins in the cell, including those associated with Ras and others associated with the cytoskeleton, the cellular machinery responsible for the protrusions. Several of these perturbations induced the protrusions--and consequently, ERK activity--giving insight on other key proteins involved in the Ras-ERK pathway.

In addition, Huang and his colleagues found that ERK activation could be triggered both by chemical stimulation with growth factors as well as mechanical stimulation when cells were grown on stiff surfaces. The researchers suggest that cells might be using these protrusions to sense the extracellular environment, triggering the Ras-ERK pathway to activate when conditions are favorable for cells to migrate and proliferate.

Huang notes that each of these findings could offer new avenues to modulate Ras-ERK activity in cancer cells.

"The more we learn about the molecular mechanism of this dynamic pathway," Huang says, "the greater the chances that we'll be able to modulate its activity not by directly targeting Ras or ERK, but by targeting other associated molecules as an alternative."

He and his colleagues are currently working to develop a more complete picture of all the different molecules involved in this complex network.
-end-
VIDEO: Breast Cancer Cell Making Protrusions

Other Johns Hopkins researchers who participated in this study include Sayak Bhattacharya, Hoku West-Foyle, Chien-Fu Hung, T.-C. Wu, and Pablo A. Iglesias.

This work was supported in part by grants from the National Institutes of Health K22CA212060, P50CA098252, R01CA183040, S10 OD018118, a Cervical Cancer SPORE Career Development Award and DARPA HR0011-16-C-0139.

Chuan-Hsiang "Bear" Huang is a member of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Johns Hopkins Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.